4-Jun-2026
Organon to Present New Research on Access and Value at ISPOR 2026
Business Wire (Fri, 15-May 7:30 AM ET)
Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 14-May 5:25 PM ET)
Globe Newswire (Wed, 6-May 9:14 PM ET)
Globe Newswire (Tue, 5-May 3:58 PM ET)
Globe Newswire (Tue, 5-May 2:53 PM ET)
Globe Newswire (Tue, 5-May 12:58 PM ET)
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 4-May 2:55 PM ET)
Organon Reports Results for the First Quarter Ended March 31, 2026
Business Wire (Thu, 30-Apr 7:30 AM ET)
Organon Cancels First Quarter Earnings Call
Business Wire (Wed, 29-Apr 7:30 AM ET)
Business Wire (Wed, 29-Apr 5:30 AM ET)
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Organon & Co. Common trades on the NYSE stock market under the symbol OGN.
As of June 4, 2026, OGN stock price was flat at $13.40 with 1,227,984 million shares trading.
OGN has a beta of 2.56, meaning it tends to be more sensitive to market movements. OGN has a correlation of 0.20 to the broad based SPY ETF.
OGN has a market cap of $3.52 billion. This is considered a Mid Cap stock.
Last quarter Organon & Co. Common reported $1 billion in Revenue and $.71 earnings per share. This fell short of revenue expectation by $-24 million and missed earnings estimates by -$.13.
In the last 3 years, OGN traded as high as $24.08 and as low as $5.69.
The top ETF exchange traded funds that OGN belongs to (by Net Assets): IJR, VTI, VB, VBR, VXF.
OGN has outperformed the market in the last year with a return of +41.4%, while the SPY ETF gained +28.3%. In the last 3 month period, OGN beat the market returning +95.3%, while SPY returned +10.8%. However, in the most recent 2 weeks OGN has underperformed the stock market by returning -0.1%, while SPY returned +1.9%.
OGN support price is $13.36 and resistance is $13.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGN shares will trade within this expected range on the day.